|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Lurbinectedin
Description of
Lurbinectedin: Lurbinectedin, also known as PM01183, is a synthetic tetrahydropyrrolo
[4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential
antineoplastic activity. DNA minor groove-binding agent PM01183
covalently binds to residues lying in the minor groove of DNA, which may
result in delayed progression through S phase, cell cycle arrest in the
G2/M phase and cell death. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer: PharmaMar USA
|
MedKoo Code#: 205594
|
|
Name: Lurbinectedin
|
|
CAS#: 497871-47-3
Synonym: PM-01183; PM 01183; PM01183.
Lurbinectedin
IUPAC/Chemical name:
Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'-[1H]pyrido[3,4-b]indol]-19-one,
5-(acetyloxy)-2',3',4',6,6a,7,9',13,14,16-decahydro-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-,
(1'R,6R,6aR,7R,13S,14S,16R)-
|
|
Chemical structure
|
Theoretical analysis
|
|
|
Chemical Formula: C41H44N4O10S
Exact Mass: 784.27781
Molecular Weight: 784.87
Elemental Analysis: C, 62.74; H, 5.65; N,
7.14; O, 20.38; S, 4.09
|
|
Availability and price:
This agent is
not in stock, may be available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
1: Bueren-Calabuig JA, Giraudon C, Galmarini CM, Egly
JM, Gago F. Temperature-induced melting of double-stranded DNA in the
absence and presence of covalently bonded antitumour drugs: insight from
molecular dynamics simulations. Nucleic Acids Res. 2011
Oct;39(18):8248-57. Epub 2011 Jul 3. PubMed PMID: 21727089; PubMed
Central PMCID: PMC3185422.
2: Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A,
Galmarini CM, Henriques JA, Escargueil AE, Larsen AK. Trabectedin and
its C subunit modified analogue PM01183 attenuate nucleotide excision
repair and show activity toward platinum-resistant cells. Mol Cancer
Ther. 2011 Aug;10(8):1481-9. Epub 2011 May 27. PubMed PMID: 21622731.
3: Leal JF, Martínez-Díez M, García-Hernández V, Moneo V, Domingo A,
Bueren-Calabuig JA, Negri A, Gago F, Guillén-Navarro MJ, Avilés P,
Cuevas C, García-Fernández LF, Galmarini CM. PM01183, a new DNA minor
groove covalent binder with potent in vitro and in vivo anti-tumour
activity. Br J Pharmacol. 2010 Nov;161(5):1099-110. doi:
10.1111/j.1476-5381.2010.00945.x. PubMed PMID: 20977459; PubMed Central
PMCID: PMC2998690.
4: Valeri A, Alonso-Ferrero ME, Cerrato L, Martínez S, Bueren JA,
Albella B. Development of an in vitro model for the simultaneous study
of the efficacy and hematotoxicity of antileukemic compounds. Toxicol
Lett. 2010 Dec 15;199(3):317-22. Epub 2010 Sep 29. PubMed PMID:
20883753.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
